Diethylstilbestrol (DES) labeled with Auger emitters: Potential radiopharmaceutical for therapy of estrogen receptor-positive tumors and their metastases?

References

• Adelstein S J. The Auger process: A therapeutic promise. American Journal of Roentgenology 1993; 160: 707
   PubMed Web of Science ®Google Scholar
• Ahnström G, Ehrenberg L, Hussain S, Natarajan A T. On the killing and mutagenic action in E. coli associated with Auger effect during 125I decay. Mutation Research 1970; 10: 247–250
   PubMedGoogle Scholar
• Albanese J, Dainiak N. Modulation of intercellular communication mediated at the cell surface and on extracellular, plasma membrane-derived vesicles by ionizing radiation. Experimental Hematology 2003; 31: 455–464
   PubMed Web of Science ®Google Scholar
• Aronson N N, Touster O. Isolation of rat liver plasma membrane fragments in isotonic sucrose. Methods in enzymology XXXI, Part A, Biomembranes, S Fleischer, L Packer. Academic Press, New York 1974
   Google Scholar
• Beckmann M W, Scharl A, Göhring U, Niederacher D, Holt J A. Durch Konversionselektronen verursachte und östrogenrezeptorvermittelte Zytotoxizität von 16alpha-Radioiod-17beta-Östradiol in Mammakarzinomzellen in vitro. Tumordiagnostik und Therapie 1994; 15: 17–20
   Google Scholar
• Bloomer W D, Adelstein S J. 5-(I-125)-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature (London) 1977; 265: 620–621
   PubMed Web of Science ®Google Scholar
• Bloomer W D, Adelstein S J. 5-(I-125)-iododeoxyuridine and the Auger effect: Biological consequences and implications for therapy. Pathobiology Annual 1978; 8: 407–421
   PubMedGoogle Scholar
• Bloomer W D, Adelstein S J. Iodine-125 cytotoxicity: implications for therapy and estimation of radiation risk. International Journal of Nuclear Medicine and Biology 1981; 8: 171–178
   PubMedGoogle Scholar
• Bloomer W D, McLaughlin W H, Adelstein S J. Therapeutic implications of iodine-125 cytotoxicity. International Journal of Radiation Oncology Biology Physics 1982; 8: 1903–1908
   PubMedGoogle Scholar
• Bloomer W D, Mc Laughlin W H, Milius R A, Weichselbaum R R, Hanson R N, Adelstein S J, Seitz D E. Estrogen receptor-mediated cytotoxicity using I-125. Journal of Cell Biochemistry 1983; 21: 39–45
   PubMed Web of Science ®Google Scholar
• Bloomer W D, McLaughlin W H, Weichselbaum R R, Hanson R N, Adelstein S J, Seitz D E. The role of subcellular localization in assessing the cytotoxicity of labeled iododeoxyuridine, iodotamoxifen, and iodoantipyrine. Journal of Radioanalytical Chemistry 1981; 65: 209–213
   Web of Science ®Google Scholar
• Bloomer W D, Mc Laughlin W H, Weichselbaum R R, Tonneson G L, Hellman S, Seitz D E, Hanson R N, Adelstein S J, Rosner A L, Burstein N A, Nove J J, Little J B. Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing estrogen receptors. International Journal of Radiation Biology 1980; 38: 197–202
   Web of Science ®Google Scholar
• Bradley E W, Chan P C, Adelstein S J. The radiotoxicity of iodine-125 in mammalian cells. I. Effects on the survival curve of radioiodine incorporated into DNA. Radiation Research 1975; 4: 555–563
   Google Scholar
• Buchegger F, Perillo-Adamer F, Dupertuis Y M, Bischof-Delaloye A. Auger radiation targeted into DNA: A therapy perspective. European Journal of Nuclear Medicine and Molecular Imaging 2006; 33: 1352–1363
   PubMed Web of Science ®Google Scholar
• Burki H J, Roots R, Feinendegen L E, Bond V P. Inactivation of mammalian cells after disintegrations of 3H or 125I in cell DNA at −196°C. International Journal of Radiation Biology 1973; 24: 363
   Web of Science ®Google Scholar
• Chan P C, Lisco E, Lisco H, Adelstein S J. The radiotoxicity of iodine-125 in mammalian cells. II. A comparative study on cell survival and cytogenetic response to I-125-UdR, I-131-UdR and H-3-TdR. Radiation Research 1976; 67: 332–343
   PubMed Web of Science ®Google Scholar
• DeSombre E R, Hughes A, Hanson R N, Kearney T. Therapy of estrogen receptor-positive micrometastases in the peritoneal cavity with Auger-electron-emitting estrogens – theoretical and practical considerations. Acta Oncologica 2000; 39: 659–666
   PubMed Web of Science ®Google Scholar
• Dodds E C, Goldberg L, Lawson W, Robinson R. Estrogenic activity of certain synthetic compounds. Nature (London) 1938; 141: 247–248
   Google Scholar
• Feinendegen L E. Biological damage from the Auger effect, possible benefits. Radiation and Environmental Biophysics 1975; 12: 85
   PubMed Web of Science ®Google Scholar
• Feinendegen L E, Henneberg P, Tisljar-Lentulis G. DNA strand breakage and repair in human kidney cells after exposure to incorporated iodine-125 and cobalt-60 γ-rays. Current Topics in Radiation Research 1977; 12: 436
   Google Scholar
• Fischer T, Schomäcker K, Schicha H. Labelling, purification, and receptor affinity of radioactive iododiethylstilbestrol (*I-DES) with high specific activity and first structure analysis with natI-DES. Journal of Labelled Compounds and Radiopharmaceuticals 2004; 47: 669–678
   Web of Science ®Google Scholar
• Goddu S M, Howell R W, Rao D V. Cellular dosimetry: Absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. Journal of Nuclear Medicine 1994; 35: 303–316
   PubMed Web of Science ®Google Scholar
• Humm J L, Howell R E, Rao D V. Dosimetry of Auger-electron-emitting radionuclides: report No.3 of AAPM Nuclear Medicine Task Group No.6. Medical Physics 1994; 21: 1901–1915
   PubMed Web of Science ®Google Scholar
• Kassis A I, Adelstein S J. Radiobiologic principles in radionuclide therapy. Journal of Nuclear Medicine 2005; 46: 4S–12
   PubMed Web of Science ®Google Scholar
• Kassis A I, Sastry K SR, Adelstein S J. Kinetics of uptake, retention, and radiocytotoxicity of I-125 IUdR in mammalian cells: Implication of localized energy deposition by Auger processes. Radiation Research 1987; 109: 78–89
   PubMed Web of Science ®Google Scholar
• Korach K S, Chae K, Gibson M, Curtis S. Estrogen receptor stereochemistry: Ligand binding and hormonal responsiveness. Steroids 1991; 56: 263–270
   PubMed Web of Science ®Google Scholar
• Krisch R E. Lethal effects of I-125 decay by electron capture in Escherichia coli and bacteriophage T1. International Journal of Radiation Biology 1972; 21: 167–189
   Web of Science ®Google Scholar
• Krisch R E, Sauri C J. Further studies of DNA damage and lethality from the decay of iodine-125 in bacteriophages. International Journal of Radiation Biology 1975; 27: 553–560
   Web of Science ®Google Scholar
• Lieberman M E, Gorski J, Jordan V C. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. Journal of Biological Chemistry 1983; 258: 4741–4745
   PubMed Web of Science ®Google Scholar
• Meller-Rehbein B, Schomäcker K, Schicha H, Bähre M, Richter E. 123I-Diethystilbestrolphophate – a potential tracer for receptorimaging and therapy?. European Journal of Nuclear Medicine 1994; 21: 878, (abstract)
   Google Scholar
• Mende T, Hennig K, Wollny G, Gens J. Experimentelle Untersuchungen über die Verteilung von intravenös injiziertem jodmarkiertem Cytonal (Diäthylstilböstroldiphosphat). Zeitschrift für Urologie und Nephrologie 1978; 71: 529–534
   PubMedGoogle Scholar
• Mende T, Hennig K, Wollny G, Gens J, Zotter S. Verteilung von Jod-markiertem Diäthylstilböstroldiphosphat nach intravenöser Injektion. Gynäkologische Rundschau 1979; 19: 30–36
   PubMedGoogle Scholar
• O'Donoghue J A, Wheldon T E. Targeted radiotherapy using Auger electron emitters. Physics in Medicine and Biology 1996; 41: 1973–1992
   PubMed Web of Science ®Google Scholar
• Sastry K SR. Biological effects of the Auger emitter iodine-125: A review. Report No 1 of AAPM Nuclear Task Group No 6. Medical Physics 1992; 19: 1361–1370
   PubMed Web of Science ®Google Scholar
• Schomäcker K, Fischer T, Böttcher B, Mraheel S A, Scharl A, Gabruk-Szostak B, Scheidhauer K, Gohring U J, Meller-Rehbein B, Shukla S K, Schicha H. Die Kinetik von rezeptorvermittelter Radiotoxizität des 16α-[125I]-Iodöstradiol-3,17β. Nuklearmedizin 1998; 37: 134–140
   PubMedGoogle Scholar
• Schomäcker K, Fischer T, Löhr H, Moka D, Scheidhauer K, Schicha H. Biokinetics of I-123-Diethylstilbestrol (DES) in mamma-carcinoma bearing mice. Journal of Nuclear Medicine 1999; 40: 100P, (abstract)
   Web of Science ®Google Scholar
• Schomäcker K, Meller-Rehbein B, Gabruk-Szostak B, Gerard H, Scheidhauer K, Scharl A. Investigations into biokinetics of I-123 Diethylstilbestrol phosphate in tumour-bearing mice. Radioactive isotopes in clinical medicine and research, H Bergmann, A Kroiss, H Sinzinger. Birkhäuser Verlag, Basel 1997; 333–342
   Google Scholar
• Tubis M, Endow J S, Blahd W H. The preparation of 131I labeled diethylstilbestrol diphosphate and its potential use in nuclear medicine. Journal of Nuclear Medicine 1967a; 5: 1–15
   Google Scholar
• Tubis M, Endow J S, Blahd W H. The distribution of 131I labeled diethylstilbestrol diphosphate in animals and men with observations on its potential use as a scanning agent of the prostate. Journal of Nuclear Medicine 1967b; 5: 184–202
   Google Scholar
• Yasui L S, Hughes A, Desombre E R. Cytotoxicity of 125I-oestrogen decay in non-oestrogen receptor-expressing human breast cancer cells, MDA-231 and oestrogen receptor-expressing MCF-7 cells. International Journal of Radiation Biology 2001; 77: 955–962
   PubMed Web of Science ®Google Scholar